Combinate BioWorks
Combination product quality systems.
Clear ownership across drug and device.
Clarify requirements, ownership, and decisions across drug and device quality systems.
Where capable systems lose clarity.
Drug and device quality systems may each work well on their own. Risk appears at the interfaces, where decisions, records, changes, and responsibilities must move across functions, sites, and external partners.
- Product and process decisions cross quality systems without one accountable owner.
- Global, site, development, and commercial roles overlap or leave gaps.
- Design, risk, change, supplier, complaint, and CAPA interfaces are not consistently connected.
- A new product, lifecycle stage, or external partner exposes responsibilities the existing system does not address.
The work can define quality-system architecture, governance, and priorities. Procedure development and ongoing operational ownership are scoped separately.